The Research Progress in Immunotherapy of Tuberculosis
Tuberculosis (TB) is a serious public health problem worldwide. The combination of various anti-TB drugs is mainly used to treat TB in clinical practice. Despite the availability of effective antibiotics, effective treatment regimens still require long-term use of multiple drugs, leading to toxicity...
Guardado en:
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Frontiers Media S.A.
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/8879e2e53777414da90bd916f9bcabc4 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:8879e2e53777414da90bd916f9bcabc4 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:8879e2e53777414da90bd916f9bcabc42021-11-15T04:56:50ZThe Research Progress in Immunotherapy of Tuberculosis2235-298810.3389/fcimb.2021.763591https://doaj.org/article/8879e2e53777414da90bd916f9bcabc42021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fcimb.2021.763591/fullhttps://doaj.org/toc/2235-2988Tuberculosis (TB) is a serious public health problem worldwide. The combination of various anti-TB drugs is mainly used to treat TB in clinical practice. Despite the availability of effective antibiotics, effective treatment regimens still require long-term use of multiple drugs, leading to toxicity, low patient compliance, and the development of drug resistance. It has been confirmed that immune recognition, immune response, and immune regulation of Mycobacterium tuberculosis (Mtb) determine the occurrence, development, and outcome of diseases after Mtb infection. The research and development of TB-specific immunotherapy agents can effectively regulate the anti-TB immune response and provide a new approach toward the combined treatment of TB, thereby preventing and intervening in populations at high risk of TB infection. These immunotherapy agents will promote satisfactory progress in anti-TB treatment, achieving the goal of “ultra-short course chemotherapy.” This review highlights the research progress in immunotherapy of TB, including immunoreactive substances, tuberculosis therapeutic vaccines, chemical agents, and cellular therapy.Jie MiYan LiangJianqin LiangWenping GongShuyong WangJunxian ZhangZhiming LiXueqiong WuFrontiers Media S.A.articleimmunotherapytuberculosisimmunoactive substancestuberculosis therapeutic vaccineschemical agentscellular therapyMicrobiologyQR1-502ENFrontiers in Cellular and Infection Microbiology, Vol 11 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
immunotherapy tuberculosis immunoactive substances tuberculosis therapeutic vaccines chemical agents cellular therapy Microbiology QR1-502 |
| spellingShingle |
immunotherapy tuberculosis immunoactive substances tuberculosis therapeutic vaccines chemical agents cellular therapy Microbiology QR1-502 Jie Mi Yan Liang Jianqin Liang Wenping Gong Shuyong Wang Junxian Zhang Zhiming Li Xueqiong Wu The Research Progress in Immunotherapy of Tuberculosis |
| description |
Tuberculosis (TB) is a serious public health problem worldwide. The combination of various anti-TB drugs is mainly used to treat TB in clinical practice. Despite the availability of effective antibiotics, effective treatment regimens still require long-term use of multiple drugs, leading to toxicity, low patient compliance, and the development of drug resistance. It has been confirmed that immune recognition, immune response, and immune regulation of Mycobacterium tuberculosis (Mtb) determine the occurrence, development, and outcome of diseases after Mtb infection. The research and development of TB-specific immunotherapy agents can effectively regulate the anti-TB immune response and provide a new approach toward the combined treatment of TB, thereby preventing and intervening in populations at high risk of TB infection. These immunotherapy agents will promote satisfactory progress in anti-TB treatment, achieving the goal of “ultra-short course chemotherapy.” This review highlights the research progress in immunotherapy of TB, including immunoreactive substances, tuberculosis therapeutic vaccines, chemical agents, and cellular therapy. |
| format |
article |
| author |
Jie Mi Yan Liang Jianqin Liang Wenping Gong Shuyong Wang Junxian Zhang Zhiming Li Xueqiong Wu |
| author_facet |
Jie Mi Yan Liang Jianqin Liang Wenping Gong Shuyong Wang Junxian Zhang Zhiming Li Xueqiong Wu |
| author_sort |
Jie Mi |
| title |
The Research Progress in Immunotherapy of Tuberculosis |
| title_short |
The Research Progress in Immunotherapy of Tuberculosis |
| title_full |
The Research Progress in Immunotherapy of Tuberculosis |
| title_fullStr |
The Research Progress in Immunotherapy of Tuberculosis |
| title_full_unstemmed |
The Research Progress in Immunotherapy of Tuberculosis |
| title_sort |
research progress in immunotherapy of tuberculosis |
| publisher |
Frontiers Media S.A. |
| publishDate |
2021 |
| url |
https://doaj.org/article/8879e2e53777414da90bd916f9bcabc4 |
| work_keys_str_mv |
AT jiemi theresearchprogressinimmunotherapyoftuberculosis AT yanliang theresearchprogressinimmunotherapyoftuberculosis AT jianqinliang theresearchprogressinimmunotherapyoftuberculosis AT wenpinggong theresearchprogressinimmunotherapyoftuberculosis AT shuyongwang theresearchprogressinimmunotherapyoftuberculosis AT junxianzhang theresearchprogressinimmunotherapyoftuberculosis AT zhimingli theresearchprogressinimmunotherapyoftuberculosis AT xueqiongwu theresearchprogressinimmunotherapyoftuberculosis AT jiemi researchprogressinimmunotherapyoftuberculosis AT yanliang researchprogressinimmunotherapyoftuberculosis AT jianqinliang researchprogressinimmunotherapyoftuberculosis AT wenpinggong researchprogressinimmunotherapyoftuberculosis AT shuyongwang researchprogressinimmunotherapyoftuberculosis AT junxianzhang researchprogressinimmunotherapyoftuberculosis AT zhimingli researchprogressinimmunotherapyoftuberculosis AT xueqiongwu researchprogressinimmunotherapyoftuberculosis |
| _version_ |
1718428816860250112 |